FGF2 and myasthenia gravis: Pretreatment with NAC and AG in the MG-treated group led to a significant increase in VEGFA, FGF2 mRNA and VEGFA, p-VEGFR2(951), VEGFR2, and caveolin-1 protein expression compared with that in the MG group.